MBHB Partner Kevin Noonan Authors Biosimilar Development Article Entitled, “Will Samsung Maintain Legendary Status With Biosimilars?”

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “Will Samsung Maintain Legendary Status With Biosimilars?” that appears in the May 16, 2016 online edition of BiosimilarDevelopment.com. Samsung, the Korean computer chipmaker powerhouse, decided several years ago to pursue the emerging global biosimilar market. Although it’s early, these efforts are bearing fruit, considering the company’s joint biologics companies — Samsung BioLogics and Samsung Bioepis — have had six biosimilar products either approved or in development. These biosimilars are of reference products that amassed aggregate sales of $40 billion in 2015. Now is a good time to be a biosimilar drug maker: the regulatory exclusivities for these drugs have generally expired years ago, and patents protecting the drugs Samsung has targeted — Enbrel, Remicade, Herceptin, Humira, Avastin, and Lantus — will expire in the next four years.  view the article